Roivant empowers a global team of innovators from within and beyond the biopharmaceutical industry.

Matt Gline serves as Chief Executive Officer of Roivant Sciences. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer. From April 2014 to March 2016, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, where he focused on technology and data strategy.

Prior to Goldman Sachs, Mr. Gline was a co-founder of Fourthree, a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President at Barclays, Enterprise Risk Management Advisory, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Mr. Gline earned his A.B. in Physics from Harvard College.

Matt Gline serves as Chief Executive Officer of Roivant Sciences. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer. From April 2014 to March 2016, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, where he focused on technology and data strategy.

Prior to Goldman Sachs, Mr. Gline was a co-founder of Fourthree, a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President at Barclays, Enterprise Risk Management Advisory, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Mr. Gline earned his A.B. in Physics from Harvard College.

Alex Gasner serves as the Executive Vice President of Roivant Health, where he leads new investments and company creation in healthtech. Mr. Gasner joined Roivant in November, 2017, and previously served as Head of Corporate Development, where he helped lead Roivant's $3b strategic alliance with Sumitomo Dainippon Pharma and the $200m investment from SK Holdings in our protein degradation platform.

Before Roivant, Mr. Gasner co-founded Bee, a retail financial services platform for low and middle-income Americans, building the company to 25,000 customers through a successful exit, after spending his early career as a management consultant. Mr. Gasner earned his B.S.E. cum laude in Mechanical Engineering from Princeton University.

Daniel Gold has served as Director of Roivant since 2020. Mr. Gold serves as the CEO, managing partner and founder of QVT Financial LP, an asset management company with offices in New York and New Delhi. QVT Financial, through its managed and affiliated multi-strategy funds, is an experienced global investor in multiple industries, including biotech, financial, shipping and offshore industries. Mr. Gold founded QVT Financial LP in 2003. Mr. Gold holds an A.B. in Physics from Harvard College. Mr. Gold also currently serves on the board of public companies MP Materials, Okeanis Eco Tankers Corp. and Awilco Drilling PLC, in addition to various private companies.

Eric has more than 15 years drug discovery experience gained at small, mid-size and large pharma/biotech companies including Merck-Serono, Novartis, and AstraZeneca.

His experience spans several therapeutic areas and drug modalities, including small molecules, macrocycles, peptides, oligonucleotides, drug conjugates, and degraders, with a track record of delivering across discovery phases, including clinical candidates and novel technologies. At AstraZeneca, he built the first New Modalities group in the industry, which paved the way for the rapid expansion of the field, later fueled by protein degradation approaches. There, he also led a corporate-wide drug discovery transformation project, which brought large investments into multiple areas including the use of AI for drug discovery. Before joining Roivant, he built a first-in-category biotech company at Flagship Pioneering, leading the R&D team from inception, and demonstrated proof-of-concept for a new modality.

Eric is coauthor/coinventor of over 65 publications, patents, posters and oral presentations. He holds a doctor of philosophy degree in organic chemistry from the University of Edinburgh in Edinburgh and a master’s of business administration from Imperial College London in London.

Eric Venker serves as President of Roivant Sciences and CEO of Immunovant. Dr. Venker first joined Roivant in 2014 and has since served in various roles of increasing responsibility, most recently as COO. Prior to joining Roivant, Dr. Venker was a physician at New York Presbyterian Hospital, Columbia University Medical Center, where he trained in internal medicine. While there, Eric served as the Chair of the Housestaff Quality Council and led operational initiatives to improve efficiencies across a large hospital system with $5 billion in annual revenue. Earlier in his career, Eric was a Clinical Pharmacist at Yale-New Haven Hospital. He received his Pharm.D. from St. Louis College of Pharmacy and his M.D. from Yale School of Medicine.

Frank Torti is the Vant Chair at Roivant Sciences, Chairman and Chief Executive Officer of Telavant, and Executive Chairman of Immunovant.

In his role at Roivant, Dr. Torti serves as Chairman, Executive Chairman, or CEO of the public and private biopharmaceutical companies (Vants) at Roivant and is responsible for those businesses. This group of companies has advanced over forty medicines into clinical development, produced positive phase three results in ten consecutive clinical trials, and generated over twelve billion dollars in value. In addition, companies created at Roivant have delivered six FDA approvals and have brought novel medicines in dermatology, oncology, immunology, men’s and women’s health, and rare disease to millions of patients.

During the course of his career, Dr. Torti has been Chairman of the Board of fifteen companies and served on more than thirty corporate boards. He has been involved in more than $22 billion in capital formation through fundraising, partnerships, and corporate acquisitions, and companies with which he has been involved have completed approximately twenty initial public offerings and M&A transactions.

Prior to joining Roivant, Dr. Torti was a partner at New Enterprise Associates (NEA), one of the largest venture capital firms in the world.

Dr. Torti received his BA with highest honors as a Morehead Scholar at the University of North Carolina, his MD from the University of North Carolina School of Medicine, and his MBA with distinction from Harvard Business School.

As chief technology officer, Huafeng oversees the development of new computational methods and models in the Roivant Discovery platform. He also provides guidance on their applications in drug discovery projects. Huafeng joined Silicon Therapeutics prior to its acquisition by Roivant Sciences.

Previously, Huafeng spent 12 years at D. E. Shaw Research, a privately held biochemistry research company based in New York, where he played an early role in the design of the specialized Anton chip for molecular dynamics simulations and led development of the methods and software for free energy calculations that are now widely used in the pharmaceutical industry. His research interests include development of simulation methods, free energy calculations, structural immunology, protein folding and misfolding and molecular design.

Huafeng earned a bachelor of science degree in chemistry from Peking University in Beijing, China and a master of science and a doctor of philosophy degree in chemical physics from Columbia University in New York."

Ian Rosenblum serves as Chief Information Officer at Roivant Sciences, leading the Information Technology and Facilities organizations. Before joining Roivant, Ian was the Vice President, Head of IT and Facilities at Agios Pharmaceuticals, where he drove the transformation of Agios into a digitally optimized, AI-forward organization. Under his leadership, the IT and Facilities teams enabled seamless hybrid work, fortified cybersecurity infrastructure, and supported key business milestones such as regulatory filings, clinical trial execution, and commercial launches.
 
With a strong foundation in both R&D and commercial technology leadership roles at Biogen and nearly a decade of consulting at Accenture, Ian brings a unique ability to translate complex business needs into scalable, secure, and innovative solutions. He has a track record of building cross-functional partnerships, optimizing digital and physical workspaces, and enabling data-driven decision-making across global organizations.

Ian earned his B.A. in Management Information Systems from Binghamton University and his M.B.A. from UNC Kenan-Flagler Business School.

Ilan Oren has served as Director of Roivant since 2014. He has served as Co-Chief Executive Officer of Dexcel Pharma, a privately-owned Israeli group of pharmaceutical companies, since November 2019. Prior to serving as Co-CEO, Ilan served as Vice President for the group and led corporate and business development activities, including formation of strategic ventures, product partnerships, product portfolio selection, product acquisitions, strategic investments, and mergers and acquisitions. He holds an A.B. in Economics from Harvard College.

Iván Cornella-Taracido is vice president of translational chemical biology at Roivant Discovery.

His team develops and leverages chemical biology and proteomics methods and workflows to support the discovery organization and translational assessment of clinical opportunities for target selection, biomarker identification, and indication expansion.

In previous roles, at Cedilla Therapeutics, Merck, AstraZeneca, and Sanofi, Iván established and managed chemical biology and proteomics teams, supporting target and drug discovery initiatives across disease areas and modalities. Before Sanofi, at Novartis, he was a founding member of the NIBR target identification and mode of action elucidation (TIDMoA) platform. Throughout his career, Iván has also acted as consultant on target and drug discovery for a number of start-ups and biotech firms.

Iván holds a Ph.D. in organic chemistry from the Universidade da Coruña, Spain, and earned an Executive Certificate in innovation from MIT Sloan School of Management. He completed postdoctoral work at the Institute of Chemistry & Cell Biology of Harvard Medical School (now the Broad Institute of MIT and Harvard), as National Cancer Institute Initiative for Chemical Genetics Research Fellow, and at the Boston College chemistry department.

Iván volunteers as committee member for the Chemistry in Cancer Research section of the AACR, and as ambassador for the non-profit organization SeedingLabs. He has been an invited speaker, organizer and chair for numerous international conferences on drug discovery, phenotypic screening, target identification, chemical biology and proteomics.

James C. Momtazee has served as a Director of Roivant since September 2021. He has held various positions at KKR & Co., Inc. (“KKR”) since 1996. He helped form KKR\'s health care industry group in 2001 and was promoted to KKR\'s Head of the Heath Care Team for the Americas Private Equity platform in January 2009. He was a member of KKR\'s Americas Private Equity Investment Committee and was Chairman of the Health Care Strategic Growth and the Health Care Royalty & Income Investment Committees. During the period between 2001 and 2019, KKR was one of the most active investors on Wall Street, committing over $50 billion in capital across the health care sector. The largest of these investments was its $33 billion acquisition of HCA, Inc. in 2006, which at the time, was the largest cash buyout in history. During this same period, KKR made several other notable investments across the health care sector, including: Jazz Pharmaceuticals plc in 2004, PRA Health Sciences, Inc. in 2013, and BridgeBio Pharma, Inc. in 2016.

Mr. Momtazee currently serves on the Board of Directors of BridgeBio, Apollo Therapeutics, Kriya Therapeutics and the Medical Device Manufacturers Association and has previously served on the Board of Directors of multiple other health care companies, including PRA Health Sciences, Inc. (lead independent director), Envision Healthcare, Heartland Dental, Ajax Health, Global Medical Response, BrightSpring Health Services, Covenant Surgical Partners, Entellus Medical, Inc. (acquired by Stryker Corporation), EchoNous, Spirox, Inc., Arbor Pharmaceuticals, Lake Region Medical, HCA Healthcare, Jazz Pharmaceuticals, and Alliance Imaging.

Jason brings more than 16 years of drug discovery and medicinal chemistry expertise to Roivant Discovery.

Prior to joining Roivant, Jason was a recognized leader in Merck’s global discovery chemistry department where he held positions of increasing responsibility, most recently as director of chemical biology, leading teams across all levels of preclinical discovery including target identification, target validation, lead identification and lead optimization. Jason was a founding member of Merck’s chemical biology group and a co-lead of Merck’s targeted protein degradation group. Jason contributed to the discovery of five development candidates, three INDs and was a co-inventor in the discovery of the beta-lactamase inhibitor Relebactam.

Jason has authored over 30 peer-reviewed journal articles and holds 12 patents spanning a diverse set of therapeutic areas. He holds a bachelor of arts degree in biology and bachelor of science degree in chemistry from the University of Massachusetts in Amherst, Mass. where he was a recognized Howard Hughes Undergraduate Research Fellow, a doctor of philosophy degree in organic chemistry from the University of Arizona in Tucson, Az. and a National Institute of Health Ruth L. Kirschstein National Research Service Award Postdoctoral Fellowship at Boston College in Chestnut Hill, Mass.

Jenni joins Roivant with over 20 years of experience and a love of technical accounting.  Most recently, she was the Global Investment Banking Controller at JPMorganChase (JPMC) where she led a global team responsible for the accounting, reporting, and internal controls over financial reporting for JPMC’s global banking businesses.  Before her time as a Controller, Jenni was in Accounting Policy at JPMC and Citi supporting various Wholesale and Consumer businesses.  She began her career in public accounting at PwC and Deloitte spending time in both the auditing and technical accounting advisory practices in Minneapolis, San Diego, London, and New York.

Jo Chen is the General Counsel at Roivant, where he is responsible for Roivant's legal, compliance, and risk management functions. He was previously general counsel at JHL Capital Group. Jo has also been an attorney at Bain Capital, D.E.Shaw & Co., and the law firm of Weil, Gotshal & Manges.

He received a J.D. from Yale Law School and an A.B. from Princeton University.

Keith Manchester has served as Director of Roivant since 2014. He serves as a Partner and the Head of Life Sciences at QVT Financial, New York, USA, an investment firm, where he has been employed since 2005. He focuses on investments in both publicly traded and privately owned life science companies. Prior to joining QVT, Dr. Manchester was Vice President of Business Development from 2002 to 2004 and Director of Business Development from 2000 to 2002 at Applied Molecular Evolution, a biotechnology company. From 1999 to 2000, Dr. Manchester was an associate at Vestar Capital Partners, a private equity firm. From 1997 to 1999, Dr. Manchester was an investment banker in the healthcare group at Goldman, Sachs & Co. He received his A.B. from Harvard College and his M.D. from Harvard Medical School. Dr. Manchester serves as a director for the following companies: Roivant Sciences Ltd., Roivant Sciences, Inc., Arbutus Biopharma Corporation, and Kriya Therapeutics. Dr. Manchester also sits on the Supervisory Board of Medigene AG.

Kelly Graff serves as Head of People at Roivant Sciences leading Human Resources and Talent Acquisition. Ms. Graff joined Roivant in 2020 and served in roles of increasing responsibility, most recently as Head of Talent Acquisition. Prior to joining Roivant, Ms. Graff worked as an executive recruiter with several boutique search firms focused on biotechnology and venture capital. Before making the pivot into life sciences, she worked in the U.S. defense and intelligence community.

Ms. Graff received her M.S. in International Relations from the University of Denver and B.S. in History from University of California, Davis.

Mayukh Sukhatme is President and Chief Investment Officer of Roivant, and also serves on our Board of Directors.  Dr. Sukhatme is responsible for identifying, performing diligence on, devising development strategies for, and transacting on new therapeutic programs for Roivant. Dr. Sukhatme also informs Roivant’s view of its existing biopharmaceutical subsidiary companies for capital allocation decisions across the Roivant portfolio. Dr. Sukhatme joined Roivant in 2015 and previously served as President of Roivant Pharma and as our Chief Business Officer. Programs that Dr. Sukhatme has in-licensed or acquired for Roivant have produced all 12 of our positive Phase 3 studies and have garnered 8 FDA approvals. From 2000 to 2015, Dr. Sukhatme was a healthcare-focused analyst and portfolio manager for several large institutional investment firms, including both public markets and venture capital firms. His principal focus was on development-stage biotechnology and pharmaceutical companies, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds across a wide variety of therapeutic areas. Dr. Sukhatme earned his M.D. from Harvard Medical School and his B.S. in Biology and B.S. in Literature from MIT.

Mayukh Sukhatme is President and Chief Investment Officer of Roivant, and also serves on our Board of Directors.  Dr. Sukhatme is responsible for identifying, performing diligence on, devising development strategies for, and transacting on new therapeutic programs for Roivant. Dr. Sukhatme also informs Roivant’s view of its existing biopharmaceutical subsidiary companies for capital allocation decisions across the Roivant portfolio. Dr. Sukhatme joined Roivant in 2015 and previously served as President of Roivant Pharma and as our Chief Business Officer. Programs that Dr. Sukhatme has in-licensed or acquired for Roivant have produced all 11 of our positive Phase 3 studies and have garnered 8 FDA approvals. From 2000 to 2015, Dr. Sukhatme was a healthcare-focused analyst and portfolio manager for several large institutional investment firms, including both public markets and venture capital firms. His principal focus was on development-stage biotechnology and pharmaceutical companies, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds across a wide variety of therapeutic areas. Dr. Sukhatme earned his M.D. from Harvard Medical School and his B.S. in Biology and B.S. in Literature from MIT.

Ms. FitzGerald is a global healthcare strategist, investor, academic and author. She has worked across the healthcare industry from front line patient care through the Fortune 500, and also serving as an Adjunct Professor of Health Policy at Columbia University. Ms. FitzGerald is a private equity investor where she serves as a senior advisor to several firms, including Goldman Sachs, Towerbrook and Wellspring. Ms. FitzGerald served from December 2016 to January 2020 as the Chief Executive Officer and Managing Partner at Letter One’s inaugural health vehicle, L1 Health. Prior to that, she spent twenty years working for many prominent healthcare companies, including Cardinal Heath, Medco Health Systems, Pfizer, Merck and Sanofi-Synthelabo. Currently, Ms. FitzGerald is a member of the board of directors of Tenet Healthcare and a founder of K2HealthVentures, a life science investment fund. She previously served as a director of Thimblepoint Acquisition Corp., from February to December 2021, and Arix Bioscience plc, from 2017 to 2019. Ms. FitzGerald received a Doctor of Public Health from New York Medical College, a Master of Public Health from Columbia University and a BSN in Nursing from Fairfield University. The Board believes that Ms. FitzGerald’s broad range of experience in the healthcare industry qualifies her to serve as a member of the Board.

Melissa Epperly has served as Director of Roivant since 2022. Ms. Epperly most recently served as Chief Financial Officer at Zentalis Pharmaceuticals, Inc., from September 2019 to April 2024. Prior to that, she served as Chief Financial Officer of PsiOxus Therapeutics Ltd., a clinical-stage gene therapy cancer company, from June 2018 to August 2019, and as Chief Financial Officer and Head of Business Development at R-Pharm US, a commercial-stage oncology company, from October 2015 to June 2018. Ms. Epperly also served as a Director at Anchorage Capital Group, a credit-focused hedge fund from August 2012 to September 2015. Ms. Epperly holds a B.A. in Biochemistry and Economics from the University of Virginia and an M.B.A from Harvard Business School.

Richard Pulik serves as Chief Financial Officer of Roivant Sciences. Mr. Pulik joined Roivant in September 2021 and brings over twenty years of industry experience. Prior to joining Roivant, Mr.Pulik was the Global Head of Business Development & Licensing and Portfolio Management, Oncology at Novartis and a member of Novartis's Innovation Management Board and the Novartis Oncology Leadership Team. Mr. Pulik joined Novartis in 2012 as a Senior Director, Mergers & Acquisitions based in Basel, Switzerland. Earlier in his career Mr. Pulik worked at Bank of America Merrill Lynch, Monitor Group and UBS Investment Bank, focusing on mergers and acquisitions and strategy in the healthcare sector.

Mr. Pulik received a B.S. in Finance from The Wharton School and a B.A. in Economics and International Relations at the University of Pennsylvania in 2001. He grew up in Slovakia, Austria and Boston, and is passionate about delivering meaningful medicines to patients globally.

Stephanie Lee Griffin serves as Chief Operating Officer, Roivant Platforms. In this role, she oversees Operations, HR, IT, Real Estate & Facilities, and Corporate Communications. Since joining Roivant in 2017, Stephanie has held several key positions, including Chief Business Officer at Lokavant, where she led the Sales, Marketing, and Customer Success organizations and drove the first four commercial partnerships for the organization, prior to its Series A financing. In addition to other operating roles, she has also served as COO of Lysovant, a Roivant subsidiary created to develop an endolysin-based novel antibacterial treatment, and Chief of Staff to the company’s previous CEO and founder.

Before her tenure at Roivant, Stephanie worked at Celgene, focusing on U.S. and global pricing strategy. She began her career as a management consultant in the pharmaceutical industry at IMS Health, advising large global pharmaceutical and medical device manufacturers. Stephanie earned her A.B. in Classics from Brown University and her M.B.A. from Columbia Business School. In addition to her professional endeavors, Stephanie is currently serving on the Board of Directors for Treehouse Shakers, a New York-based non-profit dance and theater company, for young audiences nationwide. Stephanie has previously served on the Board of Directors of the New York City Arts in Education Roundtable from 2020-2023, reflecting her commitment to community engagement and the arts.

As Vice President, Translational Informatics at Roivant Discovery, Tudor leads translational informatics efforts ranging from targets through drug discovery as we advance our pipeline of medicines to the clinic. Tudor joined Roivant Discovery from the University of New Mexico. Tudor is a digital drug hunter with three decades of experience in machine learning and knowledge management applied to target and drug discovery.

At the University of New Mexico, Tudor served as director for screening informatics and, ultimately as chief of translational informatics where he received over $24 million in extramural funding for a broad range of projects. Prior to the University of New Mexico, Tudor worked at AstraZeneca where he conceptually developed the “lead-like approach” for combinatorial chemistry and fragment-based drug discovery. Tudor co-invented the first G-protein coupled estrogen receptor agonist, an orphan drug designated compound for uveal melanoma. He has developed machine learning models since 1989, first in cheminformatics and quantitative structure-activity relationship (QSAR) and later in disease and target biology. Tudor has co-authored over 270 publications, edited two books on informatics in drug discovery, has been awarded 10 U.S. patents and has been cited nearly 23,000 times.

Tudor received his M.D. in general medicine (1990) and Ph.D. in molecular physiology (1992) from the University of Medicine and Pharmacy in Timişoara, Romania.